U.S., May 12 -- ClinicalTrials.gov registry received information related to the study (NCT07578298) titled 'THRIVE - Trial of Passive Humoral RSV Immunity for Value and Effectiveness' on May 05.
Brief Summary: RSV is a leading cause of severe respiratory illness and hospitalisation for young children, with particularly high rates of RSV respiratory infection observed amongst Aboriginal and Torres Strait Islander children living in Australia's Northern Territory. The goal of this clinical trial is to evaluate whether routinely administering a single dose of respiratory syncytial virus (RSV)-specific monoclonal antibody, nirsevimab, from 6 months old, provides protection against RSV infections for Aboriginal and Torres Strait Islander childr...